source
- Swiss biotech Windward Bio raises $165 million to launch Phase 3 asthma trial for China-derived drugSwiss biotech Windward Bio announced it has secured $165 million in financing. The capital will be used to move one of its two experimental medicines, originally discovered in China, into a Phase…
- Latus Bio secures $42 million to launch Huntington’s disease gene therapy trialBiotech startup Latus Bio announced it has raised $42 million to fund its first clinical trials, including a gene‑therapy program aimed at Huntington’s disease. The capital will be used to seek FDA…